[Funding alert] France-based Biotechnology Company Samabriva Secures €4m in Series A Round Funding

This will supplement the assistance that Banque publique d'investissement (BPI) in France and Service public de Wallonie (SPW) in Belgium have already provided. The funding will guarantee that Samabriva's technology is implemented more quickly and that the company becomes a fully-fledged CDMO.

Read also - Estonia-based Ecobase Raises €2.5M Seed Funding

Samabriva is a plant-based biotechnology firm led by CEO Marina Guillet. The company offers a platform that combines traditional bioproduction in large-scale bioreactors with the benefits of plant-based systems (low cost, safe, serum- and animal-free).

This allows for the year-round, anywhere production of a variety of high-value compounds in a consistent, dependable, and ecologically friendly manner. Its cutting-edge plant-based bioproduction method has the power to revolutionise the pharmaceutical and cosmetic industries' ability to produce high-value compounds like recombinant proteins and natural active molecules (secondary metabolites).

Read also - Metz-based i-Virtual Secures €3 Million in Funding

About Samabriva

A business called Samabriva Biotechnology is developing a novel process to use plants to make chemicals, biotech products, and biopharmaceuticals. The advantages of both conventional biomanufacturing methods and plant-based systems are combined in Samabriva's adaptable platform.

Read also - Lyon-based Axeleo Capital Secures €73 Million second Fund